Literature DB >> 30076860

A novel repetitive mild traumatic brain injury mouse model for chronic traumatic encephalopathy research.

Xintong Ge1, Jinwen Yu2, Shan Huang2, Zhenyu Yin2, Zhaoli Han2, Fanglian Chen3, Zengguang Wang4, Jianning Zhang5, Ping Lei6.   

Abstract

BACKGROUND: Athletes, military personnel and mobility-declined elderly people are prone to repetitive mild traumatic brain injury (rmTBI). The injury does not cause acute pathological changes, but leads to chronic neurodegeneration, long-term cognitive dysfunction and even chronic traumatic encephalopathy (CTE). Many existing rmTBI animal models reported uncontrollable adverse effects and long experiment period. Therefore, an improved model needs to be designed. NEW
METHOD: Our rmTBI mouse model is a modification of the closed head injury method using electronic controlled cortical impact system. Discontinuous 4 impacts with 48-h interval were performed. A key facet of the model is the use of our designed molded acrylic cast and concave metal disc (as a helmet). They could scatter and transmit hitting power to the whole brain, thus produced a mild diffused injury. The procedure does not require scalp incision or craniotomy, which allows the impacting to be completed in 2 min.
RESULTS: Our model did not induce acute macroscopic brain damage and brain edema. It could lead to sustained neuroinflammation and chronic neurodegeneration in injured brain, and resulted in cognitive dysfunction within 5 weeks post-injury. COMPARISON WITH EXISTING
METHODS: Previously reported adverse effects including skull fractures, hemorrhage and brain tissue loss were not observed in our model. An experiment period of 5 weeks was allowed for observing chronic neurodegeneration and cognitive dysfunction.
CONCLUSIONS: Our model is beneficial to use for simplicity, reproducibility and time saver. It could serve as a platform for research on the pathogenesis, diagnosis and potential therapeutics for rmTBI and CTE.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic traumatic encephalopathy; Closed-head impact; Cognitive dysfunction; Neurodegeneration; Neuroinflammation; Repetitive mild traumatic brain injury

Mesh:

Year:  2018        PMID: 30076860     DOI: 10.1016/j.jneumeth.2018.07.021

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  10 in total

1.  Increases in miR-124-3p in Microglial Exosomes Confer Neuroprotective Effects by Targeting FIP200-Mediated Neuronal Autophagy Following Traumatic Brain Injury.

Authors:  Dai Li; Shan Huang; Zhenyu Yin; Jialin Zhu; Xintong Ge; Zhaoli Han; Jin Tan; Shishuang Zhang; Jing Zhao; Fanglian Chen; Haichen Wang; Ping Lei
Journal:  Neurochem Res       Date:  2019-06-12       Impact factor: 3.996

2.  Prevention of brain damage after traumatic brain injury by pharmacological enhancement of KCNQ (Kv7, "M-type") K+ currents in neurons.

Authors:  Fabio A Vigil; Eda Bozdemir; Vladislav Bugay; Sang H Chun; MaryAnn Hobbs; Isamar Sanchez; Shayne D Hastings; Rafael J Veraza; Deborah M Holstein; Shane M Sprague; Chase M Carver; Jose E Cavazos; Robert Brenner; James D Lechleiter; Mark S Shapiro
Journal:  J Cereb Blood Flow Metab       Date:  2019-07-04       Impact factor: 6.200

3.  Mesenchymal stromal cell treatment attenuates repetitive mild traumatic brain injury-induced persistent cognitive deficits via suppressing ferroptosis.

Authors:  Dong Wang; Shishuang Zhang; Xintong Ge; Zhenyu Yin; Meimei Li; Mengtian Guo; Tianpeng Hu; Zhaoli Han; Xiaodong Kong; Dai Li; Jing Zhao; Lu Wang; Qiang Liu; Fanglian Chen; Ping Lei
Journal:  J Neuroinflammation       Date:  2022-07-14       Impact factor: 9.587

4.  Increased Microglial Exosomal miR-124-3p Alleviates Neurodegeneration and Improves Cognitive Outcome after rmTBI.

Authors:  Xintong Ge; Mengtian Guo; Tianpeng Hu; Wenzhu Li; Shan Huang; Zhenyu Yin; Ying Li; Fanglian Chen; Luoyun Zhu; Chunsheng Kang; Rongcai Jiang; Ping Lei; Jianning Zhang
Journal:  Mol Ther       Date:  2019-11-27       Impact factor: 11.454

5.  Downregulation of microRNA-9-5p promotes synaptic remodeling in the chronic phase after traumatic brain injury.

Authors:  Jingchuan Wu; Hui Li; Junchi He; Xiaocui Tian; Shuilian Luo; Jiankang Li; Wei Li; Jianjun Zhong; Hongrong Zhang; Zhijian Huang; Xiaochuan Sun; Tao Jiang
Journal:  Cell Death Dis       Date:  2021-01-05       Impact factor: 8.469

6.  Inhibition of Exosome Release Alleviates Cognitive Impairment After Repetitive Mild Traumatic Brain Injury.

Authors:  Tianpeng Hu; Zhaoli Han; Xiangyang Xiong; Meimei Li; Mengtian Guo; Zhenyu Yin; Dong Wang; Lu Cheng; Dai Li; Shishuang Zhang; Lu Wang; Jing Zhao; Qiang Liu; Fanglian Chen; Ping Lei
Journal:  Front Cell Neurosci       Date:  2022-01-27       Impact factor: 5.505

7.  A novel simple traumatic brain injury mouse model.

Authors:  Chen Chen; Jiawei Hou; Junfeng Lu; Zeyu Zhu; Yang Yang; Weijia Peng; Rongbiao Pi
Journal:  Chin Neurosurg J       Date:  2022-04-01

8.  A Novel Blood Inflammatory Indicator for Predicting Deterioration Risk of Mild Traumatic Brain Injury.

Authors:  Xintong Ge; Luoyun Zhu; Meimei Li; Wenzhu Li; Fanglian Chen; Yongmei Li; Jianning Zhang; Ping Lei
Journal:  Front Aging Neurosci       Date:  2022-04-26       Impact factor: 5.750

9.  Dependence of visual and cognitive outcomes on animal holder configuration in a rodent model of blast overpressure exposure.

Authors:  Rachael S Allen; Cara T Motz; Anayesha Singh; Andrew Feola; Lauren Hutson; Amber Douglass; Sriganesh Ramachandra Rao; Lara A Skelton; Lidia Cardelle; Katie L Bales; Kyle Chesler; Kaavya Gudapati; C Ross Ethier; Matthew M Harper; Steven J Fliesler; Machelle T Pardue
Journal:  Vision Res       Date:  2021-07-30       Impact factor: 1.886

10.  Calpain-2 as a therapeutic target in repeated concussion-induced neuropathy and behavioral impairment.

Authors:  Yubin Wang; Yan Liu; Amy Nham; Arash Sherbaf; Diana Quach; Emad Yahya; Davis Ranburger; Xiaoning Bi; Michel Baudry
Journal:  Sci Adv       Date:  2020-07-01       Impact factor: 14.136

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.